O2 Other

Cost-Effectiveness of Pasireotide Long-Acting in a Treatment of Acromegaly in Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization




List of Authors: Hahl J, Kurki S, Miettinen T, Snicker K

Publication year: 2015

Journal: Value in Health

Volume number: 18

Issue number: 7

Number of pages: 1

ISSN: 1098-3015

DOI: http://dx.doi.org/10.1016/j.jval.2015.09.2109


Abstract

The objective is to describe disease progression and treatment patterns of acromegaly in patients with inadequate biochemical control, assess how biochemical control will impact disease progression and treatment pathways and estimate the economic efficiency of pasireotide long-acting (PASI) in a treatment of acromegaly in Finland. PASI is compared to pegvisomant + somatostatin analoque (PEG+SSA) in patients with inadequately controlled acromegaly.



Last updated on 2021-24-06 at 09:27